Colon cancer: What is new in 2004?;Cancer du côlon: Quoi de neuf en 2004?

Bulletin du Cancer

Volumn 91, Issue 1, 2004, Pages 75-80

  André, Thierry ^a,c   Louvet, Christophe ^b,c   De Gramont, Aimery ^b,c   Gercor, Et Le ^c  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chemotherapy; Colon cancer; Laparoscopic surgery; Microsatelite instability

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; MONOCLONAL ANTIBODY; OXALIPLATIN;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CRYOTHERAPY; HUMAN; INTERPERSONAL COMMUNICATION; LAPAROSCOPIC SURGERY; LYMPH NODE; METASTASIS; MICROSATELLITE MARKER; PREOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDY; PUBLICATION; RADIOFREQUENCY; REVIEW; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; HUMANS; MICROSATELLITE REPEATS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1242338072     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Hill C, Doyon F. Frequency of cancer in France. Bull Cancer 2003 ; 90 : 207-13.
2. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey L, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C cancer. Br J Surg 2000 ; 87 : 1197-202.
3. Hemminski A, Meclin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000 ; 119 : 1309-10.
4. Watanabe T, Tsung-The W, Catalano PJ, Takashi U, Satriano R, Haller D, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2003 ; 344 : 1196-206.
5. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 ; 349 : 247-57.
6. Nash GM, Gimbel M, Shia J, Culliford AT, Nathanson DR, Ndubuisi M, et al. Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer. J Clin Oncol 2003 ; 21 : 3105-12.
7. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003 ; 21 : 2912-9.
8. Tournigand C, André T, Louvet C, Quinaux E, Achille E, Lledo G, et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colo-rectal cancer (MCRC). J Clin Oncol 2004 (in press).
9. André T, Louvet C, Maindrault-Goebel F, de Gramont A. Oxaliplatine en association au 5-fluoro-uracile et à l'acide folinique dans le traitement du cancer colorectal métastatique. Bull Cancer 2001 ; 88 (numéro spécial) : 20-5.
10. André T, Figer A, Cervantes A, Lledo G, Flesh M, Maindrault-Goebel F, et al. Folfox 7 compared to Folfox 4: preliminary results of the randomized Optimox study. Proc Am Soc Clin Oncol 2003 ; 22 : 253 (abstr. 1016).
11. Maughan T, James R, Kerr D, Ledermann J, McArdle V, Seymour M, et al. Continuous versus intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC Cr06b randomised trial. Lancet 2003 ; 361 : 457-64.
12. Kabbinavar F, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II randomized trial comparing bevacuzimab plus fluorouracil/leucovorin with fluorouracil/leucovorin alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 ; 21 : 60-5.
13. Hurwitz H, Fehrenbacher L, Cattwright T, Hainsworth J, Heim W, Betlin J, et al. Bevacuzimab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacuzimab in combination with bolus IFL as first-line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003 ; 22 (abst. 3646).
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab alone or in combination with irinotecan in patients with epidermal growth factor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003 ; 22 : 252 (abstr. 1012).
15. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil as adjuvant therapy of resected colon carcinoma. N Engl J Med 1990 ; 322 : 352-8.
16. Impact investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (Impact) investigators. Lancet 1995 ; 345 : 939-44.
17. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993 ; 11 : 1879-87.
18. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999 ; 17 : 3553-9.
19. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997 ; 15 : 246-50.
20. André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003 ; 21 : 2896-903.
21. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Hickish T, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003 ; 16 : 1859-65.
22. De Gramont A, Banzi M, Navarro M, Tabernero J, Hickish T, Bridgewarer J, et al. Oxaliplarin/5-FU/LV in adjuvant colon cancer: results of the international Mosaic trial. Proc Am Soc Clin Oncol 2003 ; 22 : 253 (abstr. 1015).
23. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colo-rectal cancer. J Clin Oncol 2000 ; 18 : 2938-47.
24. Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, et al. N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + Irinotecan in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 2003 ; 22 : 252 (abstr. 1009).
25. Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002 ; 359 : 2224-9.
26. Milsom JW, Smith DL, Corman ML, Howerton RA, Yellin AE, Luke DR. Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Trovafloxacin Surgical Group. Am J Surg 1998 ; 176 (6A suppl.) : S46-52.
27. Hasegawa H, Kabeshima Y, Watanabe M, Yamamoto S, Kitajima M. Randomized controlled trial of laparoscopic versus open colectomy for advanced colorectal cancer. Surg Endosc 2003 ; 17 : 636-40.
28. Curet MJ, Putrakul K, Pitchet DE, Josloff RK, Zucker KA. Laparoscopically assisted colon resection for colon carcinoma: perioperative results and long-term outcome. Surg Endosc 2000 ; 14 : 1062-6.
29. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Clinical Outcomes of Surgical Therapy (COST) Study Group. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer: a randomized trial. JAMA 2002 ; 16 : 321-8.
30. Penna C. Hepatic metastases from colorectal cancer. Bull Cancer 2003 ; 90 : 79-83.
31. Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003 ; 90 : 963-9.
32. Adam R, Pascal G, Castaing D, Azoulay D, Paule B, Levi F, et al. Liver resection for multiple colorectal metastases: influence of preoperative chemotherapy. Proc Am Soc Clin Oncol 2003 ; 22 : 296 (abstr. 1188).
33. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003 ; 21 : 3737-43.